Receptor Oligomerization and Its Relevance for Signaling by Receptors of the Tumor Necrosis Factor Receptor Superfamily.

NFκB TNF ligand superfamily TNF receptor (TNFR) family cell death receptor cluster

Journal

Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250

Informations de publication

Date de publication:
2020
Historique:
received: 08 10 2020
accepted: 28 12 2020
entrez: 1 3 2021
pubmed: 2 3 2021
medline: 2 3 2021
Statut: epublish

Résumé

With the exception of a few signaling incompetent decoy receptors, the receptors of the tumor necrosis factor receptor superfamily (TNFRSF) are signaling competent and engage in signaling pathways resulting in inflammation, proliferation, differentiation, and cell migration and also in cell death induction. TNFRSF receptors (TNFRs) become activated by ligands of the TNF superfamily (TNFSF). TNFSF ligands (TNFLs) occur as trimeric type II transmembrane proteins but often also as soluble ligand trimers released from the membrane-bound form by proteolysis. The signaling competent TNFRs are efficiently activated by the membrane-bound TNFLs. The latter recruit three TNFR molecules, but there is growing evidence that this is not sufficient to trigger all aspects of TNFR signaling; rather, the formed trimeric TNFL-TNFR complexes have to cluster secondarily in the cell-to-cell contact zone for full TNFR activation. With respect to their response to soluble ligand trimers, the signaling competent TNFRs can be subdivided into two groups. TNFRs of one group, designated as category I TNFRs, are robustly activated by soluble ligand trimers. The receptors of a second group (category II TNFRs), however, failed to become properly activated by soluble ligand trimers despite high affinity binding. The limited responsiveness of category II TNFRs to soluble TNFLs can be overcome by physical linkage of two or more soluble ligand trimers or, alternatively, by anchoring the soluble ligand molecules to the cell surface or extracellular matrix. This suggests that category II TNFRs have a limited ability to promote clustering of trimeric TNFL-TNFR complexes outside the context of cell-cell contacts. In this review, we will focus on three aspects on the relevance of receptor oligomerization for TNFR signaling: (i) the structural factors which promote clustering of free and liganded TNFRs, (ii) the signaling pathway specificity of the receptor oligomerization requirement, and (iii) the consequences for the design and development of TNFR agonists.

Identifiants

pubmed: 33644033
doi: 10.3389/fcell.2020.615141
pmc: PMC7905041
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

615141

Informations de copyright

Copyright © 2021 Kucka and Wajant.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

J Biol Chem. 2018 Jun 29;293(26):9958-9969
pubmed: 29720398
J Mol Signal. 2013 Jun 13;8(1):7
pubmed: 23758787
J Bone Miner Res. 2005 Nov;20(11):2053-60
pubmed: 16234979
J Biol Chem. 2013 May 10;288(19):13455-66
pubmed: 23532848
J Biol Chem. 2005 Dec 23;280(51):41940-52
pubmed: 16234248
Cancers (Basel). 2019 Jul 07;11(7):
pubmed: 31284696
Clin Cancer Res. 2005 Apr 15;11(8):3126-35
pubmed: 15837769
FEBS J. 2008 May;275(9):2296-304
pubmed: 18397322
J Immunol. 2009 Aug 1;183(3):1851-61
pubmed: 19596991
J Immunol. 2003 Jul 15;171(2):562-8
pubmed: 12847219
J Exp Med. 2005 May 2;201(9):1375-83
pubmed: 15851487
Mol Cell. 2010 Apr 9;38(1):101-13
pubmed: 20385093
Mol Cancer. 2014 Apr 17;13:85
pubmed: 24741998
Nat Med. 2005 Oct;11(10):1066-72
pubmed: 16170321
Cell Death Differ. 2019 Jul;26(7):1213-1220
pubmed: 30206319
J Immunol. 2017 Oct 15;199(8):2721-2728
pubmed: 28877989
Mol Cancer Ther. 2016 May;15(5):946-57
pubmed: 27037412
Science. 2011 Oct 21;334(6054):376-80
pubmed: 22021857
Blood. 2012 Jan 19;119(3):651-65
pubmed: 22053109
FASEB J. 2020 Sep;34(9):11786-11801
pubmed: 32692906
FEBS J. 2017 Apr;284(8):1131-1159
pubmed: 27865080
J Biol Chem. 2003 Feb 28;278(9):7553-7
pubmed: 12477718
Science. 2000 Jun 30;288(5475):2351-4
pubmed: 10875917
Oncogene. 2004 Apr 29;23(20):3732-6
pubmed: 15077180
J Clin Invest. 2007 Jun;117(6):1550-7
pubmed: 17492055
Mol Cell Biol. 2003 Feb;23(4):1428-40
pubmed: 12556501
PLoS One. 2013 Jun 04;8(6):e65248
pubmed: 23750247
Cell Death Dis. 2016 Aug 11;7(8):e2338
pubmed: 27512959
Nat Struct Mol Biol. 2010 Nov;17(11):1324-9
pubmed: 20935634
J Neurosci Res. 2000 Oct 15;62(2):225-33
pubmed: 11020215
Cell Death Dis. 2017 Feb 9;8(2):e2601
pubmed: 28182009
J Immunol. 1987 Sep 1;139(5):1589-96
pubmed: 2442250
Biochem J. 2003 Apr 15;371(Pt 2):395-403
pubmed: 12529173
Cell Commun Signal. 2019 Aug 5;17(1):90
pubmed: 31382980
Biochem Biophys Res Commun. 2015 Jul 31;463(3):297-302
pubmed: 26003730
Nat Immunol. 2001 Apr;2(4):333-7
pubmed: 11276204
J Immunother Cancer. 2019 Jul 19;7(1):191
pubmed: 31324216
Front Immunol. 2018 Aug 30;9:1999
pubmed: 30214450
Sci Signal. 2020 Jan 14;13(614):
pubmed: 31937565
J Immunol. 2011 Dec 1;187(11):5540-7
pubmed: 22048770
J Biol Chem. 2015 Jun 26;290(26):16330-42
pubmed: 25953898
Cancer Cell. 2018 Aug 13;34(2):331-345.e11
pubmed: 30107179
Cell Death Dis. 2014 Jan 30;5:e1035
pubmed: 24481449
Mol Cell Biol. 1998 Jan;18(1):558-65
pubmed: 9418902
Lymphokine Cytokine Res. 1994 Oct;13(5):295-301
pubmed: 7858062
Cell. 1995 Dec 1;83(5):793-802
pubmed: 8521496
ESMO Open. 2019 Jun 12;4(Suppl 3):e000510
pubmed: 31275618
Mol Cell. 2016 Oct 20;64(2):236-250
pubmed: 27746017
Nat Med. 2007 Sep;13(9):1070-7
pubmed: 17767167
J Mol Biol. 2010 Jul 2;400(1):8-15
pubmed: 20447407
Biochem J. 2009 Apr 1;419(1):185-92, 2 p following 192
pubmed: 19090789
PLoS One. 2017 Mar 21;12(3):e0174249
pubmed: 28323891
J Immunol. 2002 Dec 15;169(12):6883-9
pubmed: 12471121
J Biol Chem. 2004 Feb 27;279(9):7799-806
pubmed: 14676197
Cancer Cell. 2015 Jan 12;27(1):138-48
pubmed: 25500122
J Exp Med. 2012 Jul 2;209(7):1335-48
pubmed: 22689824
Invest Ophthalmol Vis Sci. 2005 Jan;46(1):88-95
pubmed: 15623759
Blood. 2005 Sep 15;106(6):2002-10
pubmed: 15941918
J Biol Chem. 2009 Oct 2;284(40):27567-76
pubmed: 19657145
J Biol Chem. 2012 Jan 2;287(1):484-95
pubmed: 22081603
J Biol Chem. 2003 Aug 22;278(34):32077-82
pubmed: 12773535
Cell Rep. 2019 Jun 11;27(11):3117-3123.e5
pubmed: 31189099
J Immunol. 2014 Aug 15;193(4):1828-35
pubmed: 25024386
Mol Cell. 2016 Feb 18;61(4):602-613
pubmed: 26853147
Cell. 2019 Mar 7;176(6):1477-1489.e14
pubmed: 30827683
Biochem Biophys Res Commun. 2005 May 20;330(4):1205-12
pubmed: 15823571
Science. 2000 Jun 30;288(5475):2354-7
pubmed: 10875918
Neuron. 2009 Apr 16;62(1):72-83
pubmed: 19376068
J Immunol. 2010 Aug 1;185(3):1593-605
pubmed: 20610643
J Immunol. 2011 Aug 15;187(4):1754-63
pubmed: 21742972
J Biol Chem. 1998 Dec 18;273(51):34120-7
pubmed: 9852070
J Biol Chem. 2000 Jul 7;275(27):20742-7
pubmed: 10764796
J Immunol. 1985 Dec;135(6):3972-7
pubmed: 2999236
Bioinformatics. 2020 Sep 29;:
pubmed: 32991680
J Autoimmun. 2011 Nov;37(3):160-70
pubmed: 21689905
Trends Biochem Sci. 2002 Jan;27(1):19-26
pubmed: 11796220
J Exp Med. 1997 Dec 15;186(12):2045-50
pubmed: 9396774
J Immunol. 1996 Jun 15;156(12):4622-30
pubmed: 8648105
PLoS One. 2012;7(8):e42526
pubmed: 22916132
Toxicol Sci. 2019 Jan 1;167(1):190-201
pubmed: 30202993
J Exp Med. 2014 Jun 30;211(7):1433-48
pubmed: 24958847
Leukemia. 2010 Apr;24(4):821-32
pubmed: 20147977
Immunity. 2004 Oct;21(4):461-5
pubmed: 15485624
J Cell Biol. 2005 Mar 28;168(7):1087-98
pubmed: 15795317
J Clin Invest. 2011 Mar;121(3):1174-90
pubmed: 21285513
Cancer Cell. 2018 Apr 9;33(4):664-675.e4
pubmed: 29576376
FEBS Lett. 1999 Jan 29;443(3):297-302
pubmed: 10025951
Mol Cell. 2006 Jun 9;22(5):599-610
pubmed: 16762833
Cancer Cell. 2016 Jun 13;29(6):820-831
pubmed: 27265505
J Biol Chem. 2003 Nov 14;278(46):45414-8
pubmed: 12960157
Science. 2001 Nov 30;294(5548):1945-8
pubmed: 11729324
Protein J. 2011 Apr;30(4):281-9
pubmed: 21574063
Proc Natl Acad Sci U S A. 2013 Nov 26;110(48):19501-6
pubmed: 24218606
PLoS One. 2012;7(6):e38708
pubmed: 22685601
Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1421-6
pubmed: 9990039
Cell Death Dis. 2019 Mar 4;10(3):224
pubmed: 30833543
Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):18099-104
pubmed: 16319225
Oncogene. 2002 Apr 11;21(16):2493-503
pubmed: 11971184
Sci Signal. 2012 Mar 20;5(216):ra22
pubmed: 22434933
Nature. 2009 Feb 19;457(7232):981-9
pubmed: 19225519
Biochem Biophys Res Commun. 1997 Apr 28;233(3):592-600
pubmed: 9168896
Biochim Biophys Acta. 2009 Oct;1793(10):1579-87
pubmed: 19654028
J Biol Chem. 2000 Apr 14;275(15):11121-9
pubmed: 10753918
Science. 2011 Aug 19;333(6045):1030-4
pubmed: 21852502
J Biol Chem. 1999 Dec 31;274(53):38241-50
pubmed: 10608899
MAbs. 2020 Jan-Dec;12(1):1807721
pubmed: 32840410
Cell Death Differ. 2015 Apr;22(4):643-53
pubmed: 25301068
N Engl J Med. 2018 Apr 26;378(17):1604-1610
pubmed: 29694819
J Pharmacol Exp Ther. 2001 Oct;299(1):31-8
pubmed: 11561060
J Immunol. 1988 Jul 1;141(1):21-8
pubmed: 2837508
Cell Death Differ. 2005 Jun;12(6):637-48
pubmed: 15846369
J Biol Chem. 2002 Nov 22;277(47):44953-61
pubmed: 12270937
J Invest Dermatol. 2016 Feb;136(2):541-544
pubmed: 26967487
Cell Death Differ. 2015 Nov;22(11):1727-41
pubmed: 26292758
Cancer Lett. 2013 May 28;332(2):175-83
pubmed: 21215513
Nature. 1999 Apr 8;398(6727):533-8
pubmed: 10206649
Blood. 2008 Feb 1;111(3):1004-12
pubmed: 17942754
Cancer Lett. 2013 May 28;332(2):163-74
pubmed: 21236560
J Biol Chem. 1997 Apr 18;272(16):10784-9
pubmed: 9099731
Cell. 2001 Feb 23;104(4):487-501
pubmed: 11239407
FASEB J. 2009 May;23(5):1584-95
pubmed: 19141538
J Biol Chem. 2014 Jun 6;289(23):16576-87
pubmed: 24764293
PLoS One. 2011;6(5):e19927
pubmed: 21625644
PLoS Biol. 2011 Jun;9(6):e1001090
pubmed: 21713032
Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):570-5
pubmed: 9435233
J Immunol. 2004 Dec 15;173(12):7394-400
pubmed: 15585864
J Immunol. 2005 Jun 15;174(12):7875-82
pubmed: 15944293
J Biol Chem. 2012 Jul 6;287(28):24026-42
pubmed: 22645131
Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9699-703
pubmed: 8790394
Immunity. 2016 Jul 19;45(1):209-23
pubmed: 27438772
J Biol Chem. 2002 Nov 15;277(46):44155-63
pubmed: 12215450
J Exp Med. 1998 Apr 20;187(8):1205-13
pubmed: 9547332
Cell Death Differ. 2017 Mar;24(3):500-510
pubmed: 28186505
Nature. 2009 Feb 19;457(7232):1019-22
pubmed: 19118384
Proc Natl Acad Sci U S A. 2012 Jul 3;109(27):10966-71
pubmed: 22723355
J Leukoc Biol. 2015 Nov;98(5):739-59
pubmed: 26246489
FEBS J. 2016 Jan;283(2):323-36
pubmed: 26509650
Cell Death Differ. 2012 Mar;19(3):523-33
pubmed: 21941373
J Biol Chem. 2016 Mar 4;291(10):5022-37
pubmed: 26721880
MAbs. 2014 Jan-Feb;6(1):297-308
pubmed: 24135629
Cancer Chemother Pharmacol. 2015 May;75(5):887-95
pubmed: 25721064
Cancer Cell. 2011 Jan 18;19(1):101-13
pubmed: 21251615
J Biol Chem. 2007 Jul 6;282(27):19473-80
pubmed: 17504764
EMBO J. 2007 Jan 10;26(1):221-31
pubmed: 17159907
Mol Cell Biol. 2012 Jul;32(13):2515-29
pubmed: 22547679
FEBS J. 2019 Feb;286(3):555-571
pubmed: 30589515
J Immunol. 2000 Aug 1;165(3):1322-30
pubmed: 10903733
Nat Rev Immunol. 2017 Sep;17(9):545-558
pubmed: 28580957
J Biol Chem. 2011 May 13;286(19):17015-28
pubmed: 21393245
Cell Death Differ. 2019 Jun;26(6):981-993
pubmed: 30903104
Arthritis Rheum. 2010 Aug;62(8):2424-31
pubmed: 20506390
J Biol Chem. 2013 Apr 12;288(15):10914-22
pubmed: 23463508
J Immunol. 1998 Nov 1;161(9):4753-9
pubmed: 9794406

Auteurs

Kirstin Kucka (K)

Division of Molecular Internal Medicine, Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany.

Harald Wajant (H)

Division of Molecular Internal Medicine, Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany.

Classifications MeSH